Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

References

• Blank CU, Hooijkaas AI, Haanen JB, Schumacher TN. Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother 2011; 60:1359 - 71; http://dx.doi.org/10.1007/s00262-011-1079-2; PMID: 21847631
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107:4275 - 80; http://dx.doi.org/10.1073/pnas.0915174107; PMID: 20160101
   PubMed Web of Science ®Google Scholar
• Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS ONE 2011; 6:e19499; http://dx.doi.org/10.1371/journal.pone.0019499; PMID: 21559358
   PubMed Web of Science ®Google Scholar
• Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823 - 32; http://dx.doi.org/10.1084/jem.194.6.823; PMID: 11560997
   PubMed Web of Science ®Google Scholar
• van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001; 194:481 - 9; http://dx.doi.org/10.1084/jem.194.4.481; PMID: 11514604
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 - 26; http://dx.doi.org/10.1056/NEJMoa1104621; PMID: 21639810
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011; 60:467 - 77; http://dx.doi.org/10.1007/s00262-010-0958-2; PMID: 21170646
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712 - 7; http://dx.doi.org/10.1093/annonc/mdq013; PMID: 20147741
   PubMed Web of Science ®Google Scholar
• Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy?. Clin Cancer Res 2009; 15:7116 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-09-2376; PMID: 19934296
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412 - 20; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624; PMID: 19934295
   PubMed Web of Science ®Google Scholar
• Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma. Clin Cancer Res 2012; 18:2039 - 47; http://dx.doi.org/10.1158/1078-0432.CCR-11-1823; PMID: 22271879
   PubMed Web of Science ®Google Scholar
• Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2011; http://dx.doi.org/10.1007/s00262-011-1172-6; PMID: 22146893
   PubMed Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467:596 - 9; http://dx.doi.org/10.1038/nature09454; PMID: 20823850
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507 - 16; http://dx.doi.org/10.1056/NEJMoa1103782; PMID: 21639808
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809 - 19; http://dx.doi.org/10.1056/NEJMoa1002011; PMID: 20818844
   PubMed Web of Science ®Google Scholar
• Nathanson KL. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). A.Martin, R. Letrero K. P. D'Andrea S. O'Day J. R. Infante G. S. Falchook M. Millward C. M. Curtis B. Ma R. C. Gagnon P. F. Lebowitz G. V. Long R. F. Kefford. Asco 2011. 2011. Ref Type: Abstract.
   Google Scholar
• Natarajan N, Telang S, Miller D, Chesney J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 2011; 71:1233 - 50; http://dx.doi.org/10.2165/11591380-000000000-00000; PMID: 21770473
   PubMed Web of Science ®Google Scholar
• Denardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discov 2011; 1:54 - 67; http://dx.doi.org/10.1158/2159-8274.CD-10-0028; PMID: 22039576
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9:353 - 63; http://dx.doi.org/10.1038/nri2545; PMID: 19365408
   PubMed Web of Science ®Google Scholar
• Hannani D, Sistigu A, Kepp O, Galluzzi L, Kroemer G, Zitvogel L. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 2011; 17:351 - 8; http://dx.doi.org/10.1097/PPO.0b013e3182325d4d; PMID: 21952286
   PubMed Web of Science ®Google Scholar
• Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Mackay C, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71:6997 - 7009; http://dx.doi.org/10.1158/0008-5472.CAN-11-1466; PMID: 21948969
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30:61 - 9; http://dx.doi.org/10.1007/s10555-011-9273-4; PMID: 21249425
   PubMed Web of Science ®Google Scholar
• Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010; 18:485 - 98; http://dx.doi.org/10.1016/j.ccr.2010.10.002; PMID: 21035406
   PubMed Web of Science ®Google Scholar
• den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006; 95:896 - 905; http://dx.doi.org/10.1038/sj.bjc.6603341; PMID: 16953240
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15:5379 - 88; http://dx.doi.org/10.1158/1078-0432.CCR-09-0265; PMID: 19706802
   PubMed Web of Science ®Google Scholar
• Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010; 23:820 - 7; http://dx.doi.org/10.1111/j.1755-148X.2010.00763.x; PMID: 20973932
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. Clin Cancer Res 2012; 18:1386 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479; PMID: 22156613
   PubMed Web of Science ®Google Scholar
• Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-10-0118; PMID: 20551059
   PubMed Web of Science ®Google Scholar
• Hong DS, Vence LM, Falchook GS, Radvanyi LG, Liu C, Goodman VL, et al. BRAF(V600) INHIBITOR GSK2118436 TARGETED INHIBITION OF MUTANT BRAF IN CANCER PATIENTS DOES NOT IMPAIR OVERALL IMMUNE COMPETENCY. Clin Cancer Res 2012; http://dx.doi.org/10.1158/1078-0432.CCR-11-2515; PMID: 22355009
   PubMed Web of Science ®Google Scholar
• Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41:544 - 52; http://dx.doi.org/10.1038/ng.356; PMID: 19282848
   PubMed Web of Science ®Google Scholar
• Hooijkaas AI, Gadiot J, Van der Valk M, Mooi WJ, Blank C. Targeting BRAFV600E in an inducible murine model of melanoma. 2012. Work in Revision.
   Google Scholar
• Bauer J, Büttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24:345 - 51; http://dx.doi.org/10.1111/j.1755-148X.2011.00837.x; PMID: 21324100
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949 - 54; http://dx.doi.org/10.1038/nature00766; PMID: 12068308
   PubMed Web of Science ®Google Scholar
• Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009; 4:551 - 79; http://dx.doi.org/10.1146/annurev.pathol.3.121806.151541; PMID: 19400696
   PubMed Web of Science ®Google Scholar
• Smalley KS. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 2010; 130:28 - 37; http://dx.doi.org/10.1038/jid.2009.177; PMID: 19571822
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081 - 91; http://dx.doi.org/10.1158/0008-5472.CAN-11-3722; PMID: 22237626
   PubMed Web of Science ®Google Scholar
• Cichowski K, Jänne PA. Drug discovery: inhibitors that activate. Nature 2010; 464:358 - 9; http://dx.doi.org/10.1038/464358a; PMID: 20237552
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427 - 30; http://dx.doi.org/10.1038/nature08902; PMID: 20179705
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011; 71:2750 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-10-2954; PMID: 21317224
   PubMed Web of Science ®Google Scholar
• Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012; 31:446 - 57; http://dx.doi.org/10.1038/onc.2011.250; PMID: 21725359
   PubMed Web of Science ®Google Scholar
• Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011; 117:2192 - 201; http://dx.doi.org/10.1002/cncr.25747; PMID: 21523733
   PubMed Web of Science ®Google Scholar